NecstGen

What does it take to bring a cell or gene therapy to patients? Have you ever wondered what it means to develop viral vectors, cell therapies, (ex vivo) gene therapies, and more? Watch the video. Bringing a product from R&D to production takes work. When developing a cell therapy, for example, we very closely examine the processes that our client has developed so far. We go through them, identify the critical process steps, and adjust them to achieve a GMP-compliant manufacturing process. But what is the most critical aspect of it all? We operate at the edge of scientific discovery, always keeping the patient at the centre. NecstGen helps academic and industrial Cell and Gene Therapy developers enter the clinical stage by bringing together the required expertise from R&D, development, production, QA, QC, and regulatory affairs in a 4,000 m2 development and GMP manufacturing facility. Watch the video and start exploring how we bring CGTs closer to the patients who need them. #celltherapy #genetherapy #viralvector #cdmo

Welcoming Lund University to NecstGen!   Last week, we had the pleasure of hosting a delegation from Lund University at NecstGen. Our colleagues Mandy Segers and Hanna Lammertse, PhD from Leiden University Medical Center kicked of the inspiring morning sharing an overview on the Dutch Regenerative Medicine Landscape highlighting LUMC’s comprehensive activities in the field of stem cell research. This was followed by an introduction to NecstGen, a tour through our state-of-the-art facilities for Cell & Gene Therapy development and GMP manufacturing and insightful discussions.   At NecstGen, we’re committed to empowering the next generation of therapies by fostering collaboration between academia, industry, and healthcare. The opportunity to connect with Lund University’s ATMP centers showcased the vital role of partnerships in shaping the future of innovation.   If you are interested in learning more about Lund University’s activities in the field of Cell and Gene Therapy, explore their latest ATMP pipeline report: https://lnkd.in/gGNabFE7   A big thank you to the Lund University team (Gisela Helenius, Elias Uhlin, Ola Kilsgård) for sharing their expertise and enthusiasm for ATMPs. We look forward to continuing this exciting journey of innovation and collaboration!   #cellandgenetherapy #advancedtherapies #innovation #collaboration #lunduniversity

𝐉𝐨𝐢𝐧 𝐎𝐮𝐫 𝐖𝐞𝐛𝐢𝐧𝐚𝐫: 𝐢𝐏𝐒𝐂 𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭𝐢𝐚𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐂𝐮𝐫𝐚𝐭𝐢𝐯𝐞 𝐑𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞.   Learn how induced pluripotent stem cells (iPSCs) are being developed into potentially life-changing therapies. In this webinar, our colleague Catalina Gomez-Puerto, PhD will share her expertise on iPSC-derived cell therapy development. She will discuss opportunities and challenges of iPSC differentiation and showcase practical applications with case studies.   The webinar will: · Provide a practical overview of the development and workflow of iPSCs. · Share insights on methods and strategies for the differentiation of iPSCs into specific cell types. · Highlight case studies of iPSC differentiation into Beta Cells, Dopaminergic Neurons, and RPE Cells. · Give a valuable summary on the current clinical landscape of iPSC-derived cell therapies. When: February 20th, 4 PM (CET) Where: Online, registration required   Don’t miss this chance to explore the potential of iPSCs for regenerative cell therapies. Reserve your spot today: https://lnkd.in/eSR2rCDu   #ipsc #regenerativemedicine #celltherapy #webinar #futureofmedicine

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐂𝐚𝐫𝐞𝐞𝐫 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐚𝐭 𝐍𝐞𝐜𝐬𝐭𝐆𝐞𝐧 At NecstGen, we collaborate with clients and partners to push the boundaries of what's possible in Cell & Gene Therapies to patients worldwide. We are currently seeking dedicated professionals to join our mission-driven team: 𝐌𝐚𝐢𝐧𝐭𝐞𝐧𝐚𝐧𝐜𝐞 𝐓𝐞𝐜𝐡𝐧𝐢𝐜𝐢𝐚𝐧 Ensure the upkeep of our state-of-the-art facilities and installations in compliance with GMP standards. Ideal candidates have a background in mechanical engineering and experience in a GMP environment. 𝐇𝐞𝐚𝐝 𝐨𝐟 𝐅𝐚𝐜𝐢𝐥𝐢𝐭𝐢𝐞𝐬 & 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬 Lead our Facilities & Services team, overseeing GMP facilities, engineering, warehouse, and logistics departments. A proven track record in facilities management within a GMP setting is essential. 𝐒𝐩𝐞𝐜𝐢𝐚𝐥𝐢𝐬𝐭 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 Contribute to the process development and manufacturing of innovative cell and gene therapy products. Hands-on experience with blood-derived cell products and knowledge of GMP standards are required. 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 Drive process development for cell therapy products, providing technical support for clinical trial manufacturing. A PhD or MSc in a relevant field and experience with genetically engineered cell products are necessary. At NecstGen, we offer a modern and inspiring work environment with a collegial atmosphere, a flat organisational structure, and opportunities for professional growth. Join us in shaping the future of Cell & Gene Therapies. Explore these opportunities, read about colleague stories, and more on our careers page. https://lnkd.in/gXDv4YYh

Today, Tristan Pritchard-Meaker represents NecstGen at the Dutch Life Sciences conference in Oegstgeest, just minutes from NecstGen’s home base. The event has already been a dynamic platform for sharing insights and exploring advancements in life sciences. This morning, the session on “Impact Investing: How it helps the value proposition of entrepreneurs” moderated by Carine Van Den Brink was a standout. Rachel Abbott, CEO of Pan Cancer T, one of NecstGen’s valued partners, delivered an inspiring presentation on how strategic investment can drive progress in cell therapy—a critical area for NecstGen and its mission of advancing next-generation therapies to the clinic. The conference has also provided excellent opportunities for networking, with professionals from academia and industry exchanging ideas to improve patient outcomes through innovative solutions. Later today, the “Strategies to Extend Runway and Lower Costs in Life Sciences” session, moderated by Margien Boels, PhD from Phlox Therapeutics tackled the critical challenges of rising costs and funding constraints, offering actionable insights into maintaining quality and efficiency while reducing expenses. This topic resonates deeply with our recent webinar on reducing lentivirus manufacturing costs, where we shared practical insight in how to use DOE to reduce the cost of vector manufacturing. It’s a critical conversation for advancing Cell & Gene Therapies and ensuring therapies remain accessible to patients. If you’re here at CORPUS Nederland, we’d love to connect and discuss how NecstGen contributes to solutions that drive innovation while managing costs.

Join NecstGen at the Dutch Life Sciences Conference 2024 Tristan Pritchard-Meaker will represent NecstGen at the Dutch Life Sciences conference on December 12, 2024, at the CORPUS Congress Centre in Oegstgeest. This event gathers professionals from the life sciences sector to discuss advancements and foster collaborations. Date: December 12, 2024 Venue: CORPUS Congress Centre, Oegstgeest The program includes engaging panel discussions on topics such as the investment landscape in cell therapy and strategies for meeting sustainability challenges in manufacturing. We're also looking forward to the announcement of the Venture Challenge Fall 2024 winner, showcasing some of the most innovative startups in the field. Tristan will be available throughout the day to discuss NecstGen's offerings in GMP-compliant manufacturing and process development and opportunities for collaboration to bring advanced therapies closer to patients. We look forward to engaging with fellow professionals in our local area. To arrange a meeting with Tristan during the conference, please reach out directly.

Innovation Mission: Strengthening Regenerative Medicine Collaboration between the Netherlands and the UK This week, the Dutch LSH Economic Mission to the United Kingdom brings together key players in Medical Technology, Digital Health and innovative therapies such as regenerative medicine and Cell and Gene Therapy to share insights, connect across borders, and explore opportunities for advancing therapies for patients. Tuesday‘s program held at the Wellcome Collection in London provided a valuable platform to foster collaboration between Dutch and British stakeholders. Representing NecstGen, our colleague, Tristan Pritchard-Meaker participated in a panel discussion on cost-effective production and infrastructure, alongside other experts. The conversation focused on practical solutions to make therapies more accessible while addressing challenges in scaling up manufacturing. Yesterday’s visit to Stevenage provided a brilliant opportunity to connect with the local Cell and Gene Therapy ecosystem including site visits at AstraZeneca and Cell and Gene Therapy Catapult. Joining forces with other RegMed XB pilot factory organizations – Leiden University Medical Center (LUMC) (Hanna Lammertse, PhD), Innovation Center for Advanced Therapies (ICAT) (Joost van Duijn, Renske ten Ham, Eva van Ingen, PhD), Smart BioMaterials Consortium (SBMC) (Juliette van den Dolder), and ReGEN Biomedical – the mission highlights the importance of shared knowledge and partnerships in regenerative medicine. The economic mission is organized by the Netherlands Enterprise Agency (Netherlands Enterprise Agency (RVO) | Partner in Sustainable Development) and supported by the Ministry of Foreign Affairs, the Dutch Embassy in London, and other key partners. It sets the stage for building stronger ties and addressing shared challenges in delivering advanced therapies to patients. Thank you to all involved for facilitating these meaningful connections. #regenerativemedicine #collaboration #costeffectivetherapies #NLinUK

Are you curious about how to achieve cost reductions in cell & gene therapy manufacturing? If you missed our recent webinar, Reducing Lentivirus Costs: A DOE Case Study, you can now watch the replay and gain valuable insights into strategies for improving cost-efficiency in lentiviral vector (LV) manufacturing. Lentiviral vectors are essential for CAR T cell therapies, but the high cost of plasmid DNA used in transfection-based production remains a key challenge. During the webinar, Diederik Lokhorst, viral vector specialist at NecstGen, shared how we use Design of Experiments (DOE) to address this issue reducing the cost of goods (COG) for LV manufacturing. What you’ll learn in the replay:  - An inside look at transfection-based lentivirus production  - ⁠DOE as a tool to understand and improve your manufacturing process - ⁠A Case study applying DOE to reduce LV Manufacturing Costs for CAR T If you have additional questions, we’d love to hear them! Ask away, and let’s explore how innovation can drive affordability in cell & gene therapy manufacturing. Watch the webinar replay here: https://lnkd.in/eH3H7P-F #lentivirus #cellandgenetherapy #processdevelopment

At NecstGen, our team upholds the highest process development and manufacturing standards. These efforts happen behind the scenes and are essential to everything we do. These tasks are expected and necessary for any CDMO and they deserve recognition for their importance in protecting patients and ensuring safe outcomes.   Take it from Beckley Kungah Nfor, PhD, Senior Scientist Viral Vector, who joined us in August 2024:   "My team is responsible for the development of cost-effective viral vector production platforms and the cGMP manufacturing of viral vectors for Cell & Gene Therapies (CGTs) in NecstGen's State-of-the-Art facility. Working for a non-profit CDMO like NecstGen has truly been a rewarding experience so far."   Through teamwork, multidisciplinary projects, and external collaborations, we help bring these life-changing treatments from the laboratories to the clinic and, so to patients.   "The societal impact of the work we do is immense. By advancing novel but highly underfunded Cell & Gene Therapies, we're contributing to a future where no patient is left behind," Beckley adds.   Are you interested in joining NecstGen on our mission to accelerate Cell & Gene Therapies to patients worldwide? Explore open positions on our website: https://lnkd.in/gXDv4YYh

Innovation in Action: NecstGen’s Insights from ATMP Sweden 2024 Day 1 at ATMP Sweden 2024 was packed with thought-provoking insights and conversations that showcased the growing potential of advanced therapeutic medicinal products (ATMPs). Yesterday’s sessions covered a wide range of critical topics shaping the field of advanced therapies. Discussions included auditing processes for FIH ATMP clinical trials, innovations and pressing needs in ATMP analytics, and the transformative potential of human pluripotent stem cell-derived therapies. A standout keynote by Malin Parmar highlighted groundbreaking work on dopaminergic neuron progenitors for Parkinson’s disease. Her insights into regenerative medicine demonstrated how ATMPs push boundaries in treating complex neurodegenerative disorders. The day concluded with a focus on adapting healthcare processes to accommodate both clinical trials and market-approved ATMPs, emphasizing the integration of these therapies into the healthcare system. At NecstGen, we were thrilled to share our DOE Case Study on Cost Reduction of Lentivirus Manufacturing for CAR T during the poster session in the evening and discuss its implications with attendees. The questions, feedback, and discussions reinforce the importance of collaboration and shared knowledge in advancing this field. We’re looking forward to more exciting sessions today and continuing the momentum. If you haven’t already, visit our booth #46 or connect with our colleagues Sophia and André to learn more about how we’re empowering the next generation of advanced therapies. Let's shape the future of advanced therapies together!